In a recent editorial in EyeNet on the importance of collaboration in successful research, past-president of the American Academy of Ophthalmology, Ruth Williams, M.D. cites Dr. Novack. Dr. Novack stated “…You cannot be successful unless you realize that you do NOT know everything”. Further she states that “…major breakthroughs usually require a multi-disciplinary approach, ophthalmic researcher must recognize and woo individuals who may not currently be working on vision research”. A prime example of this is the Glaucoma Research Foundation’s “Catalyst for a Cure”.
Please see the first issue of OIS Press with updates on novel ophthalmic therapies. I provide a perspective in recent US FDA approvals (Pages 9 and 11).
Dr. Novack’s article on pharmacological prophylaxis of myopia was published in a special issue of Eye and Contact Lens. This issue (Volume 44 / Issue Number 4, July 2018) features articles on Myopia Control: Current thoughts and future research. It was edited by Drs. Penny A. Asbell and Kazuo Tsubota. The publication is based upon a symposium held in November 2017 in Tokyo at Keio University. The issue includes authors from a wide variety of perspectives. All agree – myopia is an epidemic that will continue to take medical resources to deal with the increasing number of affected patients worldwide.
Dr. Gary Novack was quoted in an article on ophthalmic drug delivery in the May 2018 issue of ASCRS‘s EyeWorld. Dr. Novack pointed out “…In considering what molecules might be most likely to succeed in a sustained delivery approach…this depends on the type of delivery system. If it’s a zero order, i.e., constant delivery with respect to time system, a molecule like brimonidine or timolol is most appropriate,” … “If it’s a pulsatile, i.e., peaks and troughs system, a molecule like the prostaglandins is the better choice.” Dr. Novack has published several articles on issues in ophthalmic drug delivery, and worked on a number of successful products in this area.
There’s a lot of talk and confusion of the issues involved in the role of compounding pharmacies for topical ocular medications (eyedrops). Please see this interview in EyeWorld in which I am interviewed about regulatory issues. I address the special role which compounding pharmacies have played in the therapeutic process as physicians tailor therapies to individual patients. At the same time, I discuss the issues in the use of compounding pharmacies for larger populations crossing state lines.
One of Dr. Novack’s articles was the most popular Ophthalmology article on Medscape (Novack GD, Cannabinoids for treatment of glaucoma, Curr Opin Ophthalmol. 2016 Mar;27(2):146-50).